XI’AN, China, Oct. 15 /Xinhua-PRNewswire-FirstCall/ -- Skystar Bio-Pharmaceutical Co., Ltd (OTC Bulletin Board: SKBI) ("Skystar"), a leading bio-pharmaceutical company in the People’s Republic of China ("PRC"), today announced the launch of its new Cure King brand of veterinary medicines.
The Cure King brand is currently comprised of 26 products in three categories of Western and traditional Chinese medicines ("TCM"). The first category includes eight injectable medicines aimed at treating diarrhea, mastitis, secondary infections caused by viruses, respiratory infections, loss of appetite and other infectious diseases in pigs. The second category has 11 products in powder form that address intestinal infections, respiratory infections and diseases in young birds, as well as coccidiosis, ovaritis and nutrient-deficient diseases in chickens. The third category includes seven compound TCMs that focus on treating diarrhea, viral infections, slow gastrointestinal movements and colds in livestock. All 26 medicines have been approved by the Ministry of Agriculture for GMP-certified production. Skystar plans to increase its Cure King portfolio to meet ongoing market demand based on market response and disease cycles.
"Based on nationwide market research, we have found certain diseases to be prevalent in livestock. A unified brand targeting the treatment of these diseases is precisely what the market needs given the lack of consistency and number of inferior medicines on the market. We are committed to addressing this unmet need and enhancing our market penetration by providing reliable, effective and quality treatments," commented Mr. Weibing Lu, CEO and Chairman of Skystar.
Skystar will market the Cure King line through regular advertisements in major trade publications along with a brochure that contains in-depth information on a variety of common diseases and specific instructions for the appropriate treatments. The Company also provides seminars in local villages to educate farmers on diagnosing and treating various livestock aliments. Cure King is a registered trademark brand.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company’s product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The Company recently completed construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of management and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Such factors include, but are not limited to the Company’s ability to develop new products, market acceptance of the company’s new products, ability to obtain the regulatory approvals or clearances that are necessary to commercialize its products, ability to protect proprietary rights, political and economic factors in the People’s Republic of China and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact
Scott Cramer
Director -- U.S. Representative
Skystar Bio-Pharmaceutical Co., Ltd
Tel: +1-407-645-4433
Email: scramer@skystarbio-pharmaceutical.com
Crocker Coulson, President
CCG Elite Investor Relations
Email: crocker.coulson@ccgir.com
Leslie Richardson, Financial Writer
CCG Elite Investor Relations
Tel: +1-310-231-8600 x122
Email: leslie.richardson@ccgir.com
